These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23803217)

  • 21. [The expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma].
    Liu Y; Chen X; Peng S; Fang H; Wu Y; Peng C; Shi L; Bai M; Xu B; Wang J; Deng G
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1553-6. PubMed ID: 12609066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Cytokeratin-19 Concentration to Assess Early Recurrence and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma following Radical Resection in Patients with a Low Serum Alpha-Fetoprotein Concentration.
    Wang ZS; Guo WD; Wu LQ; Yi X; Geng C; Li YJ; Yao RY
    PLoS One; 2015; 10(11):e0142727. PubMed ID: 26588210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased Expression of ZWINT is Associated With Poor Prognosis in Patients With HCC After Surgery.
    Yang XY; Wu B; Ma SL; Yin L; Wu MC; Li AJ
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794190. PubMed ID: 30198401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence.
    Gao J; Feng X; Inagaki Y; Song P; Kokudo N; Hasegawa K; Sugawara Y; Tang W
    Biosci Trends; 2012 Aug; 6(4):153-9. PubMed ID: 23006961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma.
    Ichikawa T; Yamamoto T; Uenishi T; Tanaka H; Takemura S; Ogawa M; Tanaka S; Suehiro S; Hirohashi K; Kubo S
    J Hepatobiliary Pancreat Surg; 2006; 13(3):245-51. PubMed ID: 16708303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway.
    Takeishi K; Taketomi A; Shirabe K; Toshima T; Motomura T; Ikegami T; Yoshizumi T; Sakane F; Maehara Y
    J Hepatol; 2012 Jul; 57(1):77-83. PubMed ID: 22425622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of Fibrogenic Markers in Tumor and Tumor-Surrounding Tissue at Time of Transplantation Correlates with Recurrence of Hepatocellular Carcinoma in Patients Undergoing Liver Transplantation.
    Kocabayoglu P; Piras-Straub K; Gerken G; Paul A; Herzer K
    Ann Transplant; 2017 Jul; 22():446-454. PubMed ID: 28729525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.
    Yi X; Luk JM; Lee NP; Peng J; Leng X; Guan XY; Lau GK; Beretta L; Fan ST
    Mol Cell Proteomics; 2008 Feb; 7(2):315-25. PubMed ID: 17934217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection.
    von Felden J; Heim D; Schulze K; Krech T; Ewald F; Nashan B; Lohse AW; Wege H
    BMC Cancer; 2017 Jan; 17(1):60. PubMed ID: 28100188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis.
    Wang PC; Hu ZQ; Zhou SL; Zhan H; Zhou ZJ; Luo CB; Huang XW
    Future Oncol; 2018 May; 14(12):1177-1186. PubMed ID: 29316827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
    Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
    Noh CK; Wang HJ; Kim CM; Kim J; Yoon SY; Lee GH; Cho HJ; Yang MJ; Kim SS; Hwang JC; Cho SW; Roh J; Kim YB; Kim SJ; Kim BW; Cheong JY
    Anticancer Res; 2018 Jul; 38(7):4101-4109. PubMed ID: 29970536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence of Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy.
    Zou H; Zhu CZ; Wang C; Wang ZS; Ma X; Han B; Wu LQ
    Am J Med Sci; 2017 Sep; 354(3):262-267. PubMed ID: 28918833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.
    Jeng YM; Chang CC; Hu FC; Chou HY; Kao HL; Wang TH; Hsu HC
    Hepatology; 2008 Oct; 48(4):1118-27. PubMed ID: 18802962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.
    Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
    J Cancer Res Clin Oncol; 2006 Sep; 132(9):547-55. PubMed ID: 16763805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.
    Hou KZ; Fu ZQ; Gong H
    World J Gastroenterol; 2015 Jan; 21(2):475-83. PubMed ID: 25593462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy.
    Ji F; Zhang Y; Zhu ZB; Guo Y; Shen SL; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
    Hum Pathol; 2019 Apr; 86():193-202. PubMed ID: 30529751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients.
    Shi Z; Liu J; Yu X; Huang J; Shen S; Zhang Y; Han R; Ge N; Yang Y
    Ann Surg Oncol; 2016 Jan; 23(1):211-7. PubMed ID: 25824262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of OCT4 is associated with low differentiation and tumor recurrence in human hepatocellular carcinoma.
    Dong Z; Zeng Q; Luo H; Zou J; Cao C; Liang J; Wu D; Liu L
    Pathol Res Pract; 2012 Sep; 208(9):527-33. PubMed ID: 22824146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.